BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Medtronic Q4 Earnings Beat Overshadowed by Weak FY26 Guidance
Medtronic Q4 Earnings Beat Overshadowed by Weak FY26 Guidance
9
3
Medtronic plc delivered a strong fourth-quarter performance, with adjusted earnings per share rising 11% to $1.62, beating analyst expectations. Revenue grew 4% year-over-year to $8.93 billion, fueled by robust performance in cardiovascular and diabetes segments.
Despite these results, investors reacted negatively to the company’s cautious fiscal 2026 outlook. The disappointing forward guidance sent shares down 0.79% to $85.80, underscoring market concerns about future growth prospects.
The medical device Maker announced plans to spin off its diabetes business into a separate publicly traded company within 18 months. This strategic move failed to offset investor disappointment with the underwhelming long-term projections.
By:
Previous
World Network Secures $135M to Scale Orb-Based Digital ID Expansion in U.S.
Next
NVIDIA Unveils 800V HVDC Architecture for AI Data Centers
